

The Systemic Effects of Hydrolyzed Collagen Supplementation on Skeletal and Dermal Integrity in Aging: A Comprehensive Review of Mechanistic Pathways and Clinical Evidence

Section 1: The Collagen Matrix in Bone and Dermis: A Physiological and Age-Related Perspective

The structural integrity and functional resilience of the human body are profoundly dependent on the extracellular matrix (ECM), a complex network of proteins and polysaccharides that provides scaffolding and biochemical support to surrounding cells. Central to this matrix are the collagens, the most abundant proteins in mammals, which form the architectural framework of all connective tissues.¹ Among the 28 identified types of collagen, Type I and Type III are of paramount importance for the structure and function of bone and skin, the two organ systems most visibly affected by the aging process.² Understanding the physiological roles of these specific collagens and the mechanisms by which they degrade over time is fundamental to evaluating the therapeutic potential of interventions such as oral collagen supplementation. This section provides a detailed overview of the architectural roles of Type I and Type III collagen, the pathophysiology of their age-related decline, and the critical role of collagen cross-linking in determining tissue quality.

1.1 The Architectural Roles of Type I and Type III Collagen in Connective Tissues

Type I and Type III collagens are fibrillar collagens that frequently coexist and interact to

define the mechanical properties of tissues.³ Their distribution and specific functions, however, are tailored to the unique demands of each tissue.

In the skeletal system, Type I collagen is the undisputed organic cornerstone, comprising approximately 90% of the organic matrix of bone.⁵ Synthesized primarily by osteoblasts, Type I collagen molecules self-assemble into highly organized, striated fibrils that form a laminated scaffold.⁶ This organic framework, known as osteoid, is essential for bone's biomechanical properties; it confers tensile strength, toughness, and a degree of flexibility that prevents brittleness.⁹ The precise, quarter-staggered alignment of collagen fibrils within this matrix also serves as the template for the orderly deposition of hydroxyapatite crystals, the mineral component that provides bone with its hardness and compressive strength.⁷ Thus, the quantity and quality of the Type I collagen matrix are primary determinants of bone strength and its resistance to fracture.¹¹ While Type I is dominant, a small amount of Type III collagen is also present in bone, particularly during development and fracture healing, where it may play a role in regulating the fibril diameter of Type I collagen.¹²

In the dermis, the structural interplay between Type I and Type III collagen is more balanced and synergistic. Together, they constitute up to 75% of the skin's dry weight and form the bulk of the dermal ECM.¹³ Type I collagen forms thick, stiff fibers that provide the skin with its robust tensile strength, preventing it from tearing under stress.⁴ In contrast, Type III collagen, often found alongside Type I within the same fibrils, forms thinner, more elastic reticular fibers.² Type III collagen is crucial for the initial stages of wound healing and is believed to be essential for the proper maturation and organization of Type I collagen fibers.⁴ The interaction between these two collagen types is critical for regulating the architecture of collagen bundles, which ultimately dictates the skin's elasticity, firmness, and resilience.³ Biochemical studies have confirmed that the ratio of Type I to Type III collagen remains remarkably consistent at all levels of the dermis, underscoring their codependent functional relationship.³

1.2 The Pathophysiology of Collagen Aging: Fibroblast Senescence, Reduced Synthesis, and Defective Mechanical Stimulation

The process of chronological aging is characterized by a progressive and systemic decline in collagen homeostasis, leading to the functional and aesthetic deterioration of tissues like bone and skin.¹⁶ This decline is not a passive process but an active biological cascade involving reduced synthesis, increased degradation, and impaired cellular function. Collagen production begins to decrease in early adulthood, typically in the 20s, and this decline accelerates significantly in women following menopause due to the loss of estrogen's

supportive role in collagen synthesis.¹⁹

The cellular basis for this decline resides primarily with the fibroblast in the skin and the osteoblast in bone. Research has identified two principal mechanisms that contribute to the reduced synthesis of fibrillar (Type I and III) collagens in chronologically aged skin. The first is an intrinsic, age-dependent alteration in cellular function, often termed cellular fibroblast aging. In-vitro experiments have conclusively shown that dermal fibroblasts isolated from elderly individuals (80+ years) produce significantly less Type I procollagen—the precursor to mature collagen—than fibroblasts from young adults (18-29 years) (versus ;).²² This demonstrates an inherent reduction in the synthetic capacity of aged cells.

The second, and perhaps more insidious, mechanism is a loss of appropriate environmental cues, described as defective mechanical stimulation.¹⁶ Healthy fibroblasts require mechanical tension, provided by their attachment to an intact and organized collagen matrix, to maintain robust synthetic activity. In aged skin, this matrix becomes progressively fragmented due to chronic exposure to intrinsic and extrinsic factors, such as reactive oxygen species (ROS) and an age-related increase in the activity of matrix metalloproteinases (MMPs), enzymes that cleave collagen fibers.¹⁷ Ultrastructural studies reveal that in aged skin, fibroblasts exhibit significantly less attachment to the surrounding collagen network (58% of cell surface attached in old skin vs. 78% in young skin;

) and are less spread out.²² This fragmented, disorganized matrix fails to provide the necessary tensional homeostasis, which signals the fibroblasts to down-regulate the synthesis of new collagen.

This phenomenon creates a self-perpetuating negative feedback loop, a vicious cycle of degradation that accelerates tissue decline. Initial damage from aging processes leads to collagen fragmentation. This fragmentation then causes defective mechanical stimulation of resident fibroblasts, which in turn suppresses their ability to synthesize new, healthy collagen to repair the damage. The failure to replace damaged material exacerbates the matrix's structural decay, leading to further loss of mechanical signaling and a continued downward spiral in tissue integrity. The quantitative impact of this cycle is profound, with in-vivo measurements demonstrating a 68% decrease in Type I procollagen content in aged skin compared to young skin, reflecting a severe deficit in ongoing collagen synthesis.²² Concurrently, the proportion of the more elastic Type III collagen also diminishes in the skin over time, further contributing to the loss of youthful biomechanical properties.²³

1.3 Collagen Cross-Linking in Tissue Maturation and Senescence: Enzymatic vs. Non-Enzymatic Glycation (AGEs)

The biomechanical properties of collagenous tissues are determined not only by the quantity of collagen but, critically, by the quality and nature of the covalent bonds, or cross-links, that form between individual collagen molecules. These cross-links are essential for stabilizing collagen fibrils and providing them with tensile strength.⁶ The aging process is characterized by a significant shift in the profile of these cross-links, moving from beneficial, enzymatically controlled bonds to detrimental, non-enzymatic modifications that degrade tissue quality.¹⁶ This highlights a crucial concept: bone and skin quality are determined by more than just density or volume. The health of the underlying organic matrix is a key determinant of function and fragility.

During tissue maturation, newly synthesized collagen fibers are stabilized through a highly regulated enzymatic process mediated by the enzyme lysyl oxidase (LOX).⁶ This process forms immature divalent cross-links that subsequently mature into stable, trivalent cross-links, such as pyridinoline (PYD) and deoxypyridinoline (DPD).²⁴ These enzymatic cross-links are essential for the normal mechanical function of tissues, providing the collagen network with toughness and post-yield ductility, which is the ability to absorb energy and resist fracture after initial microdamage has occurred.²⁴ Pathological conditions such as osteoporosis have been associated with a significant reduction in the quantity of these beneficial enzymatic cross-links, contributing to bone fragility independent of changes in bone mineral density (BMD).²⁴

In stark contrast, with advancing age, collagen becomes progressively modified by a non-enzymatic process known as glycation.¹⁶ In this reaction, reducing sugars like glucose react with the amino groups of proteins to form irreversible, detrimental cross-links called Advanced Glycation End Products (AGEs). Examples of prominent AGEs found in bone and skin include pentosidine and glucosepane.²⁴ The accumulation of AGEs is a hallmark of aging and is significantly accelerated in metabolic disorders such as diabetes mellitus.¹⁶

Functionally, AGEs are deleterious to tissue quality. They render the collagen matrix stiffer, more brittle, and less capable of effectively absorbing and dissipating mechanical energy.¹⁶ In bone, an increased concentration of AGEs like pentosidine is strongly correlated with reduced bone toughness, increased accumulation of microdamage, and a higher risk of fragility fractures, even in individuals with normal or only slightly reduced BMD.²⁴ This age-related shift from a tough, flexible matrix stabilized by enzymatic cross-links to a stiff, brittle matrix laden with AGEs provides a powerful mechanistic explanation for the decline in bone and skin quality during senescence. It also establishes a clear rationale for therapeutic strategies aimed at improving the quality of the collagen matrix itself, beyond simply addressing mineral content or collagen volume.

Section 2: Clinical Efficacy of Collagen Supplementation on Skeletal Integrity in Aging Populations

The age-related decline in bone mass and quality, clinically defined as osteopenia and osteoporosis, represents a major public health concern, particularly among postmenopausal women.⁸ Given that Type I collagen forms the organic scaffold of bone, nutritional strategies aimed at supporting the collagen matrix have garnered significant scientific interest. A growing body of evidence from randomized, placebo-controlled clinical trials suggests that long-term supplementation with specific hydrolyzed collagen peptides can positively influence skeletal integrity by improving bone mineral density and favorably modulating the dynamics of bone turnover.

2.1 Impact on Bone Mineral Density (BMD): A Synthesis of Placebo-Controlled Trials

Bone Mineral Density (BMD), measured by dual-energy X-ray absorptiometry (DXA), is the clinical standard for diagnosing osteoporosis and assessing fracture risk.²⁵ The most compelling evidence for the efficacy of collagen supplementation on BMD comes from a rigorous, randomized, placebo-controlled, double-blinded investigation by König et al..²⁶ This pivotal study enrolled 131 postmenopausal women with primary, age-related reduction in BMD (osteopenia or osteoporosis). Participants received either 5 grams of specific collagen peptides (SCP) or a placebo (maltodextrin) daily for 12 months.

The results were statistically and clinically significant. The group receiving SCP demonstrated a significant increase in BMD at both the lumbar spine and the femoral neck compared to the placebo group, which experienced the expected age-related decline.²⁶ When analyzed relative to the control group's decline, the SCP group exhibited an impressive 4.2% higher BMD in the spine and a 7.7% higher BMD in the femoral neck after one year of treatment.²⁹ These findings strongly suggest that collagen peptide supplementation can not only halt but also begin to reverse age-related bone loss at critical skeletal sites.

The durability of this effect was investigated in a subsequent 4-year, open-label follow-up study involving 31 women from the original trial.³⁰ Participants who continued the daily 5-gram SCP supplementation showed a sustained and clinically relevant increase in BMD over the entire 4-year period. Absolute BMD increased by 5.79% to 8.16% in the spine and by 1.23% to

4.21% in the femoral neck.³¹ This long-term observation is particularly noteworthy, as it demonstrates that the benefits of collagen supplementation are not transient but can effectively counteract the expected trajectory of bone loss over an extended period. Furthermore, no fractures were reported among the participants during the follow-up, suggesting a potential contribution to improved bone stability and fracture prevention.³¹

These primary findings are supported by broader analyses. A recent meta-analysis concluded that collagen peptide supplementation is associated with significant improvements in BMD of the femoral neck and spine.¹¹ The analysis also noted that these effects may be synergistic, with enhanced outcomes observed when collagen is co-supplemented with calcium and vitamin D.¹¹ The collective evidence from these placebo-controlled trials provides a strong basis for the use of specific collagen peptides as a therapeutic measure to improve bone density in aging populations.

Table 1: Summary of Key Placebo-Controlled Trials on Collagen Supplementation and Bone Health

Study (Author, Year)	Population (N, Age, Condition)	Intervention (Product, Dose, Duration)	Placebo	Key Bone Outcomes (Δ vs. Placebo)	Significance (p-values)
König et al. (2018) ²⁶	131 postmenopausal women; Avg. age 64.3; Age-related reduced BMD	Specific Collagen Peptides (SCP); 5 g/day; 12 months	Maltodextrin	Δ T-score Spine: +0.13 Δ T-score Femoral Neck: +0.10 Δ P1NP: Increased in SCP group Δ CTX-1: Increased in placebo group	Spine: Femoral Neck: P1NP: CTX-1:
Zdzieblik	31	Specific	Open-label	Sustained	Spine (Y2):

et al. (2021) ³⁰	postmeno pausal women; Reduced BMD (Follow-up from König et al.)	Collagen Peptides (SCP); 5 g/day; 4 years total	I follow-up (no placebo)	increase in BMD Spine: +5.79% to +8.16% Sustained increase in BMD Femoral Neck: +1.23% to +4.21%	Spine (Y4): Fem. Neck (Y2-Y4):
Elam et al. (as cited in ¹¹)	Postmeno pausal women with osteopeni a	Hydrolyze d Collagen + Calcium + Vitamin D	Calcium + Vitamin D	Noticeably smaller decrease in BMD in the collagen group	Not specified
Hooshman d et al. (as cited in ¹¹)	Postmeno pausal women	Collagen Peptides + Calcium + Vitamin D	Not specified	Strong positive effect on BMD (SMD > 1.7)	Not specified

2.2 Modulation of Bone Turnover: Analysis of Formation (P1NP) and Resorption (CTX) Markers

The observed increases in BMD are mechanistically explained by a favorable shift in the balance of bone remodeling, the continuous physiological process of old bone removal (resorption) and new bone deposition (formation).³⁰ This balance is assessed through the measurement of specific biochemical markers of bone turnover in the blood.³² The König et al. study provided critical insights into this mechanism by analyzing two key markers: the amino-terminal propeptide of type I procollagen (P1NP), a direct indicator of bone formation by osteoblasts, and the C-telopeptide of type I collagen (CTX-1), a marker of bone resorption

by osteoclasts.²⁶

The results revealed a clear shift towards a net anabolic state in the collagen-supplemented group. Plasma levels of P1NP increased significantly in the SCP group (), directly demonstrating that the supplementation stimulated osteoblasts to synthesize more new Type I collagen matrix.²⁶ This finding is particularly significant because it points towards a specific, targeted biological effect rather than a general nutritional benefit. If collagen were acting merely as a source of amino acids, one would not necessarily expect a specific upregulation of a pro-peptide marker for bone formation. The increase in P1NP strongly supports the hypothesis that specific bioactive peptides within the hydrolysate act as signaling molecules, directly instructing osteoblasts to increase their synthetic activity.

Concurrently, the study found that levels of the resorption marker CTX-1 increased significantly in the placebo group () but remained stable in the SCP group.²⁶ This indicates that collagen supplementation effectively counteracted the expected age-related increase in bone resorption. In the normal course of postmenopausal aging, the rate of bone resorption typically exceeds the rate of formation, leading to a net loss of bone mass. The dual action observed in the trial—actively increasing bone formation (\uparrow P1NP) while simultaneously attenuating the rise in bone resorption (stabilizing CTX-1)—is the key to achieving a net positive effect on bone mass. By tilting the remodeling balance back in favor of anabolism, collagen peptide supplementation directly addresses the underlying pathophysiology of age-related bone loss, which culminates in the clinically measured improvement in BMD.

2.3 Bone Microarchitecture: Evidence from Preclinical Models and Implications for Human Bone Quality

While BMD is a crucial measure, it does not fully capture bone strength, which is also heavily dependent on bone quality and microarchitecture—the three-dimensional organization of the bone's internal structure.²⁸ Bone is composed of a dense outer layer (cortical bone) and a spongy, porous inner network (trabecular bone).⁷ Trabecular bone, found in areas like the vertebrae and the ends of long bones, has a much higher surface area and metabolic rate, making it more responsive to changes in bone turnover and crucial for load-bearing capacity.³⁵

Direct assessment of bone microarchitecture in human clinical trials is challenging due to the invasive nature of bone biopsies (histomorphometry) or the limited availability of high-resolution imaging techniques like micro-computed tomography (micro-CT).³⁴ Consequently, much of the direct evidence for the effects of collagen supplementation on microarchitecture comes from well-established preclinical animal models, particularly the

ovariectomized (OVX) rat model, which effectively mimics the estrogen-deficient bone loss seen in postmenopausal women.³⁹

Multiple studies using this model have demonstrated positive effects on bone structure. One investigation found that treatment with collagen peptides (CP) was associated with partial prevention of the deterioration in bone microarchitecture, specifically showing improvements in trabecular number (Tb.N) and trabecular separation (Tb.Sp).⁴¹ Another study in an OVX mouse model reported that collagen hydrolysates could reverse the deterioration of bone microarchitecture, as evidenced by micro-CT scans showing an increase in bone surface area, percent bone volume (BV/TV), and trabecular number, along with a corresponding decrease in trabecular separation.⁴³ A study using low-molecular-weight collagen peptides (LMWCP) in OVX rats also reported significant improvements in bone morphometric parameters, further suggesting that supplementation can help preserve the structural integrity of trabecular bone.⁴⁴

While direct human evidence remains limited, an indirect measure known as the Trabecular Bone Score (TBS) can be derived from standard DXA scans. TBS is a textural analysis of the lumbar spine image that correlates with 3D bone microarchitecture and fracture risk, independent of BMD. One randomized trial in elite cyclists, a population at risk for low BMD, investigated the effects of jump training combined with 15 g/day of hydrolyzed collagen.⁴⁵ While the study's primary outcome was BMD, it also measured TBS. The results showed that the intervention preserved femoral neck BMD and was associated with an increase in TBS in both the intervention and control groups, though the difference between groups was not statistically significant.⁴⁵ Although not conclusive, this finding provides a preliminary indication that collagen supplementation, particularly when combined with mechanical loading, may have beneficial effects on bone microarchitecture in humans.

Section 3: Dermatological Impact of Oral Collagen Peptides: Evidence from Placebo-Controlled Trials

The visible signs of skin aging—wrinkles, loss of elasticity, and dryness—are direct consequences of the structural and compositional changes within the dermal matrix, primarily the degradation of the collagen network.¹⁷ As a result, the field of dermatology has shown immense interest in "inside-out" approaches to skin health, with oral collagen supplementation emerging as a leading strategy. A substantial body of evidence from placebo-controlled clinical trials and systematic reviews now supports the efficacy of hydrolyzed collagen peptides in improving key dermatological parameters, including dermal collagen structure, skin biomechanics, and surface topography.

3.1 Enhancement of Dermal Collagen Density and Reduction of Matrix Fragmentation

Beyond subjective assessments, modern clinical trials employ sophisticated, non-invasive imaging techniques to directly visualize and quantify changes within the dermal structure. A landmark 12-week, randomized, double-blind, placebo-controlled study provided direct evidence of dermal matrix remodeling following supplementation with a product containing hydrolyzed collagen and vitamin C.⁴⁹ Using in-vivo reflectance confocal microscopy, a technique that allows for high-resolution imaging of skin layers, the researchers observed a significant

44.6% decrease in the fragmentation of the dermal collagen network in the supplemented group compared to placebo ().⁴⁹ This finding is of profound importance. As established previously, a fragmented collagen matrix is not only functionally inferior but also actively suppresses new collagen synthesis by fibroblasts. By reducing fragmentation, supplementation helps to restore a more organized and mechanically competent matrix, which is crucial for breaking the age-related cycle of degradation and promoting a healthier signaling environment for dermal cells. The same study, using high-resolution ultrasound, also suggested that these structural improvements occurred predominantly in the upper dermal compartment, the region most relevant to surface appearance.⁴⁹

These findings are strongly corroborated by systematic reviews of the literature. A comprehensive 2019 review published in the *Journal of Drugs in Dermatology*, which analyzed 11 studies involving 805 patients, concluded that oral collagen supplements lead to a demonstrable increase in **dermal collagen density** after 8 to 12 weeks of consistent use.¹³ Another review similarly noted that supplementation resulted in a remarkable increase in collagen density within the dermis.¹⁴ This collective evidence confirms that oral collagen peptides do not just affect skin feel or appearance but induce measurable, positive structural changes in the foundational matrix of the skin.

Table 2: Summary of Key Placebo-Controlled Trials on Collagen Supplementation and Dermal Health

Study (Author, Year)	Population (N, Age)	Interventio n (Product, Dose,	Placebo	Key Dermal Outcomes (Δ vs.	Significan ce (p-values)

		Duration)		Placebo)	
Reilly et al. (2024) ⁴⁹	Healthy women	Hydrolyzed Collagen + Vit C; 12 weeks	Placebo	Δ Collagen Fragmentation: -44.6% Δ Hydration: +13.8% Δ Elasticity (R2): +22.7% Δ Wrinkles (Rz): -19.6%	Fragmentation: Hydration: Elasticity: Wrinkles:
Bolke et al. (2019) ⁵⁰	72 healthy women; 35+ years	Collagen Peptides + vitamins/minerals; 2.5 g/day; 12 weeks	Placebo drink	Significant improvement in skin hydration, elasticity, roughness, and density	Not specified
Kim et al. (2018) ⁵⁰	Healthy women; 30-60 years	Low-Molecular-Weight Collagen Peptide (LMWCP); 1 g/day; 12 weeks	Placebo	Significant improvement in hydration and elasticity	Not specified
Lee et al. (2023) ⁵¹	100 women; 30-60 years	Collagen Peptide NS; 1.65 g/day; 12 weeks	Placebo	Significant improvement in hydration, elasticity, and wrinkling	Not specified

Addor et al. (2021) 52	80 healthy women; 30+ years	LMW Collagen Peptides; 2.5 g/day; 6 weeks	Placebo	Δ Moisturization: +34% Δ Wrinkle Volume: -46% Δ Wrinkle Area: -44% Δ Wrinkle Depth: -9%	All
---------------------------	--------------------------------	---	---------	---	-----

3.2 Improvements in Skin Biomechanics: Elasticity and Hydration

The structural improvements in the dermal matrix translate directly into enhanced biomechanical properties, namely skin elasticity (the ability to stretch and recoil) and hydration (moisture content). The evidence for these benefits is robust, supported by a large-scale meta-analysis and numerous individual RCTs.

A 2023 systematic review and meta-analysis, which aggregated data from 26 RCTs encompassing 1,721 patients, provides the highest level of evidence for these effects.⁵³ The pooled results demonstrated that supplementation with hydrolyzed collagen (HC) led to a highly significant improvement in

skin hydration (overall effect: $Z = 4.94$,) and a similarly significant improvement in **skin elasticity** (overall effect: $Z = 4.49$,) when compared to placebo groups.⁵³

These aggregated findings are reflective of the consistent results seen in individual, well-designed trials. For instance, the 12-week trial by Reilly et al. used cutometry to measure elasticity and corneometry for hydration, finding a 22.7% increase in the R2 elasticity index and a 13.8% increase in skin hydration, both statistically significant over placebo ().⁴⁹ Another 6-week trial focusing on low-molecular-weight collagen peptides reported an even greater relative increase in skin moisturization, with the collagen group showing a 34% greater improvement than the placebo group (

).⁵² Systematic reviews consistently echo these outcomes, concluding that oral collagen supplementation reliably increases both skin elasticity and hydration.¹³

The clinical data suggests a potential cascade of improvement, where enhancements in skin

hydration may manifest earlier than those in elasticity. Some studies report significant improvements in hydration within 4 to 8 weeks, while more profound changes in elasticity, which are dependent on the slower process of structural protein synthesis and remodeling, typically require 8 to 12 weeks or more to become significant.⁴⁷ This may reflect a two-stage mechanism, beginning with a more rapid biochemical effect—such as the stimulation of hyaluronic acid synthesis by fibroblasts, a key molecule for skin moisture—followed by the more substantial and time-consuming process of rebuilding the dermal collagen network.⁵³

3.3 Quantifiable Effects on Wrinkle Reduction and Skin Topography

The ultimate aesthetic goal of many anti-aging interventions is the reduction of visible rhytides, or wrinkles. Clinical trials have moved beyond subjective grading to employ objective, quantitative methods like 3D optical profilometry and advanced imaging systems to measure changes in wrinkle depth, volume, and area. The evidence from these studies indicates that collagen supplementation can lead to a significant and measurable reduction in wrinkles.

In the 12-week trial by Reilly et al., profilometry measurements showed a **19.6% decrease in the Rz index**, a parameter that reflects the average depth of wrinkles, in the collagen group compared to the placebo group ().⁴⁹ An even more dramatic effect was observed in a 6-week study by Addor et al., which used an advanced facial imaging system. This trial reported that participants receiving low-molecular-weight collagen peptides experienced significant reductions in

wrinkle volume by 46%, wrinkle area by 44%, and wrinkle depth by 9%, all of which were highly significant compared to the placebo group ().⁵²

These robust findings from individual RCTs are supported by the conclusions of multiple systematic reviews. The consensus in the literature is that oral supplementation with hydrolyzed collagen promotes a decrease in wrinkle formation and an overall improvement in skin smoothness and topography.⁴⁸ The reduction in wrinkles is the logical and visible culmination of the underlying structural and biomechanical improvements: a denser, less fragmented collagen network provides better support to the epidermis, while increased hydration plumps the skin from within, collectively leading to a smoother skin surface.

Section 4: Underlying Biochemical Mechanisms of

Action

The consistent clinical benefits of hydrolyzed collagen supplementation observed in both skeletal and dermal tissues are underpinned by a series of specific biochemical and cellular mechanisms. Ingested collagen is not merely a passive source of amino acids; rather, specific peptides derived from its hydrolysis act as bioactive signaling molecules that actively modulate the behavior of target cells. This section elucidates the journey of these peptides from ingestion to their effects on osteoblasts, osteoclasts, and fibroblasts, providing a mechanistic framework for the observed clinical outcomes.

4.1 Bioavailability and Cellular Targeting of Bioactive Collagen Peptides

The efficacy of any oral supplement is contingent upon its bioavailability—the extent to which its active components are absorbed and become available at the site of action. Native collagen, with its large, triple-helix structure, is poorly absorbed. The process of hydrolysis, however, uses enzymes to break down native collagen into a mixture of low-molecular-weight peptides, significantly enhancing its digestibility and absorption.⁸

Research has shown that following oral ingestion of hydrolyzed collagen, a significant portion is broken down into individual amino acids. However, a crucial fraction, consisting of specific di- and tri-peptides, is absorbed intact into the bloodstream.⁵⁸ Among these, peptides containing the amino acid hydroxyproline, which is nearly unique to collagen, are particularly noteworthy. Peptides such as proline-hydroxyproline (Pro-Hyp) and glycine-proline-hydroxyproline (Gly-Pro-Hyp) have been identified in human blood within an hour of ingestion.⁵³ These specific bioactive peptides are relatively resistant to further enzymatic degradation in the bloodstream and have been shown to be transported to and accumulate in target tissues, including the skin, cartilage, and bone.⁵³ This systemic delivery and accumulation in collagen-rich tissues is the essential prerequisite for their biological activity, allowing them to exert effects far from the site of absorption.

4.2 Stimulation of Osteoblast Proliferation and Differentiation: Impact on Bone Matrix Synthesis

Once they reach the bone microenvironment, bioactive collagen peptides exert a direct, stimulatory effect on osteoblasts, the cells responsible for bone formation.⁹ Numerous in-vitro studies using osteoblast cell lines have demonstrated that treatment with collagen peptides leads to increased cell proliferation, enhanced differentiation into mature osteoblasts, and greater deposition of mineralized matrix.⁴³

This cellular stimulation is driven by the activation of specific intracellular signaling pathways. Evidence points to the involvement of the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway, which is known to be essential for osteoblast growth and differentiation.⁶³ Other studies have implicated the PI3K/AKT signaling pathway, another critical regulator of cell growth and survival, in mediating the osteogenic effects of collagen peptides.⁴³ It has been proposed that certain peptides may function analogously to growth factors, binding to cell surface receptors like the Epidermal Growth Factor Receptor (EGFR) to initiate these signaling cascades.⁴³

The downstream effect of this signaling is a significant upregulation of genes critical for bone formation. Studies have shown that collagen peptides increase the expression of *Runt-related transcription factor 2 (RUNX2)*, the master transcription factor for osteoblast differentiation, as well as genes for key matrix proteins including *Collagen type I alpha 1 chain (COL1A1)* and *Osteocalcin (OCN)*.⁴⁴ This genetic upregulation is coupled with an increase in the activity of alkaline phosphatase (ALP), an enzyme characteristic of mature, matrix-synthesizing osteoblasts.⁴⁴ The cumulative result of these actions is a robust increase in the synthesis of the organic bone matrix (osteoid), primarily composed of Type I collagen, which provides the necessary scaffold for subsequent mineralization and leads to the accrual of new bone tissue.¹⁰ This mechanism directly explains the increase in the bone formation marker P1NP and the subsequent rise in BMD observed in human clinical trials.

4.3 Modulation of Osteoclast Activity and the OPG/RANKL Axis

The net increase in bone mass is a function not only of increased formation but also of controlled resorption. Evidence suggests that collagen peptides also contribute to this balance by modulating the activity of osteoclasts, the cells responsible for bone breakdown.⁹

A key regulatory system in bone remodeling is the OPG/RANKL axis. Receptor activator of nuclear factor kappa-B ligand (RANKL) is a cytokine that is essential for the differentiation and activation of osteoclasts. Osteoprotegerin (OPG), in contrast, acts as a decoy receptor, binding to RANKL and preventing it from activating osteoclasts. The ratio of OPG to RANKL is therefore a critical determinant of bone resorption activity; a higher ratio favors reduced resorption.⁹ Preclinical studies indicate that collagen peptides can increase the OPG/RANKL

ratio, thereby creating an anti-resorptive environment and inhibiting the excessive formation of osteoclasts.⁹

Furthermore, collagen peptides may exert an indirect anti-resorptive effect through their anti-inflammatory properties. Pro-inflammatory cytokines, such as interleukin-1 β (IL-1 β) and tumor necrosis factor- α (TNF- α), are known to promote bone loss by upregulating the expression of RANKL.⁶² In-vitro and in-vivo studies have shown that administration of collagen peptides can reduce the levels of these pro-inflammatory molecules.⁹ By dampening this inflammatory signaling, collagen peptides can further suppress the stimulus for osteoclast recruitment and activity. This dual mechanism—directly modulating the OPG/RANKL ratio and indirectly reducing pro-resorptive inflammatory signals—explains the stabilization of the bone resorption marker CTX-1 seen in clinical trials, contributing to the overall net anabolic effect on bone.

4.4 Upregulation of Dermal Fibroblast Activity and Extracellular Matrix Production

The mechanisms by which collagen peptides benefit the skin closely parallel their actions in bone, highlighting a conserved mode of action on collagen-producing cells. Upon reaching the dermis, circulating bioactive peptides, particularly Pro-Hyp, directly stimulate dermal fibroblasts.⁵⁶

This stimulation triggers a comprehensive upregulation of ECM synthesis. In-vitro studies have demonstrated that fibroblasts treated with collagen peptides increase their production of not only Type I and Type III collagen but also other essential matrix components like elastin and hyaluronic acid.⁴⁸ The increased synthesis of hyaluronic acid, a potent humectant, is a key mechanism behind the clinically observed improvements in skin hydration.⁵³

At the genetic level, these peptides have been shown to upregulate the expression of the COL1A1 gene in fibroblasts.⁶¹ Critically, this anabolic signal is often coupled with a catabolic inhibitory effect. Evidence suggests that collagen peptides can simultaneously inhibit the activity of MMP-1 and MMP-3, the very enzymes responsible for breaking down the existing collagen matrix.⁶¹ This dual-action mechanism—simultaneously boosting the synthesis of new matrix components while protecting the existing matrix from degradation—effectively shifts the metabolic balance in the dermis towards net synthesis and repair. This provides a direct biochemical explanation for the observed clinical outcomes of increased dermal density, reduced collagen fragmentation, improved elasticity, and diminished wrinkle depth. The evidence elevates collagen supplementation from a simple nutritional strategy to a bioactive intervention with quasi-pharmacological properties, where specific peptides act as signaling

molecules to instruct target cells to alter their behavior in a therapeutically beneficial manner.

Section 5: A Correlative Analysis: The Systemic Impact on Bone and Dermal Tissues

A central tenet of the user's query is the correlation between the effects of collagen supplementation on skeletal and dermal health. While the existing body of clinical research has largely investigated these two organ systems in isolation, a correlative analysis built upon the foundation of shared biochemical mechanisms and the principle of systemic bioavailability allows for a robust, evidence-based inference. The data strongly suggests that the benefits of collagen supplementation are not tissue-specific but are part of a coordinated, systemic response in collagen-rich connective tissues throughout the body.

5.1 Shared Mechanisms: A Common Pathway for Osteoblast and Fibroblast Stimulation

The biological basis for a strong correlation between bone and skin effects lies in a unified mechanism of action. As detailed in Section 4, the primary mechanism involves the systemic circulation of specific bioactive peptides (e.g., Pro-Hyp) that are absorbed after ingestion of hydrolyzed collagen.⁵³ These peptides have been shown to act as signaling molecules that stimulate the primary collagen-producing cells in both bone (osteoblasts) and skin (fibroblasts).⁶¹

This parallel stimulation is biologically plausible and consistent, as both osteoblasts and fibroblasts are of mesenchymal origin and share fundamental signaling pathways that regulate ECM synthesis.⁸ In both cell types, collagen peptides have been demonstrated to upregulate the expression of the

COL1A1 gene, leading to an increased synthesis of Type I collagen.⁶¹ This common outcome is precisely what is measured, albeit through different markers, in clinical trials: an increase in the bone formation marker P1NP (a direct product of Type I procollagen synthesis by osteoblasts) and an increase in dermal collagen density (reflecting increased synthesis by fibroblasts).¹³ Therefore, the same circulating stimulus triggers a similar anabolic response in the key synthetic cells of both tissues. This shared pathway is the fundamental link that

underpins the expected correlation between improvements in skeletal and dermal integrity.

5.2 Inferring Correlation in the Absence of Direct Dual-Endpoint Clinical Trials

A comprehensive review of the available placebo-controlled trials reveals a notable gap in the literature: there are currently no published long-term studies designed to simultaneously measure validated bone health endpoints (e.g., BMD, P1NP, CTX) and high-level dermatological endpoints (e.g., wrinkle profilometry, dermal density) within the same aging cohort.¹ The research has progressed along two parallel but separate tracks, one focused on osteoporosis and the other on skin aging.

In the absence of such a direct, head-to-head study, the correlation must be established through logical inference based on the available mechanistic and clinical data. The inferential argument is constructed as follows:

1. **Systemic Bioavailability is Proven:** Oral supplementation with hydrolyzed collagen leads to the dose-dependent appearance of specific, bioactive peptides in the systemic circulation.⁵³
2. **Independent Efficacy is Proven:** These circulating peptides have been demonstrated in separate, high-quality, placebo-controlled trials to exert statistically significant and clinically relevant positive effects on bone matrix synthesis (Section 2) and dermal matrix synthesis (Section 3).
3. **Shared Mechanism is Established:** The underlying mechanism for these effects is the stimulation of collagen-producing cells (osteoblasts and fibroblasts) via common signaling pathways (Section 4).

Given that the same stimulus (circulating peptides) is delivered systemically to both target tissues and acts via analogous mechanisms, it is highly plausible that an individual who demonstrates a positive response in one tissue will also demonstrate a positive response in the other. This leads to a critical "responder" hypothesis: the primary variable determining efficacy is likely an individual's ability to effectively absorb the bioactive peptides and the responsiveness of their cellular machinery to the peptide signals. In an individual who is a "responder," the benefits should be systemic. Conversely, a "non-responder" (due to poor absorption, genetic factors, or other metabolic reasons) would likely see little to no benefit in either tissue. The correlation, therefore, is not just between the tissues themselves, but is rooted in the individual's systemic physiological response to the intervention.

While the response is expected to be correlated, the magnitude and timeline will inevitably differ between tissues. Bone remodeling is a significantly slower process than dermal cellular

turnover. This explains why bone studies typically require longer intervention periods (12 months or more) to detect significant changes in a macro-level outcome like BMD, whereas significant improvements in skin parameters like hydration and elasticity can often be measured within 8 to 12 weeks.¹³

5.3 The Role of Systemic Bioactive Peptides in Coordinated Tissue Regeneration

The collective evidence strongly suggests that hydrolyzed collagen supplementation should be viewed not as a targeted treatment for a single condition (e.g., wrinkles or bone loss) but as a systemic agent that supports the health of the body's entire collagenous framework. The bioactive peptides do not selectively target one organ; they are distributed via the bloodstream to all collagen-rich tissues, including bone, skin, cartilage, tendons, and ligaments.⁵⁷

This systemic effect positions collagen peptide supplementation as a potential foundational strategy for mitigating the widespread, age-related degradation of the musculoskeletal and integumentary systems. By addressing a common underlying pathophysiology—the declining capacity to synthesize and maintain a healthy ECM—this approach offers a more holistic benefit than therapies that target isolated symptoms. It represents a shift from treating the disparate manifestations of aging to supporting the fundamental structural protein that is compromised in all of them. This coordinated effect on multiple tissues is the logical consequence of delivering a bioactive stimulus systemically.

Section 6: Critical Assessment, Clinical Implications, and Future Research Directions

While the evidence supporting the use of hydrolyzed collagen peptides for bone and skin health in aging populations is compelling, a critical appraisal of the literature is necessary to understand its strengths, limitations, and the key questions that remain unanswered. This final section provides a balanced evaluation of the current state of knowledge, discusses the practical clinical implications, and outlines critical directions for future research to solidify the role of this intervention in geriatric and dermatological medicine.

6.1 Evaluating the Strength of Evidence: Study Heterogeneity, Funding Bias, and Population Specificity

The overall strength of evidence for collagen supplementation is considerable but varies by endpoint. The strongest evidence exists for the improvement of BMD in postmenopausal women and for the enhancement of skin hydration and elasticity in aging women, as these outcomes are supported by multiple randomized controlled trials (RCTs) and, in some cases, systematic reviews and meta-analyses.²⁶ However, several limitations must be acknowledged.

A significant concern within the field of nutraceuticals is the potential for **funding bias**. A substantial portion of the published research on collagen supplements is funded by the companies that manufacture and market these products.¹ While this does not invalidate the findings of well-designed, placebo-controlled studies, it necessitates a cautious and critical interpretation of the results and highlights the need for more independently funded research.

Another major limitation is **product heterogeneity**. The term "collagen supplement" encompasses a vast range of products that differ in their source (bovine, porcine, marine), the type of collagen used (I, II, III, or a mix), the enzymatic hydrolysis process, and the resulting molecular weight and specific peptide profile.¹¹ The positive results observed with "specific bioactive collagen peptides" in studies like König et al. cannot be automatically extrapolated to all collagen products on the market.²⁶ The efficacy is likely dependent on the presence and concentration of specific bioactive peptides like Pro-Hyp, which may vary significantly between products.⁶¹ Furthermore, as supplements, these products are not regulated by the Food and Drug Administration (FDA), meaning there is no standardization of purity, potency, or efficacy.¹

Finally, **population specificity** is a key consideration. The most robust bone health studies have focused almost exclusively on postmenopausal women with pre-existing osteopenia or osteoporosis.²⁶ While this is a clinically relevant and high-risk group, the findings may not be generalizable to men, premenopausal women, or younger individuals.¹¹ Similarly, skin health studies have predominantly enrolled healthy women, and effects may differ in populations with specific dermatological conditions.

6.2 Gaps in the Literature: The Need for Human Microarchitectural Data and Direct Correlational Studies

Despite the progress made, several critical gaps remain in the scientific literature. First and

foremost is the lack of a **direct correlational study**. As highlighted in Section 5, the absence of a single, long-term RCT that prospectively measures validated bone and skin endpoints in the same aging cohort is the most significant unanswered question. Such a study is essential to move the bone-skin correlation from a strong inference to a proven clinical fact.

Second, there is a clear deficit of **human data on bone microarchitecture and quality**. While preclinical studies in animal models are promising, they are not a substitute for human evidence.⁷¹ Future trials should incorporate advanced, non-invasive imaging techniques like high-resolution peripheral quantitative computed tomography (HR-pQCT) to directly assess changes in trabecular and cortical microarchitecture in response to supplementation. Additionally, investigating the effects on collagen cross-linking in humans, perhaps through the measurement of serum or urinary biomarkers of AGEs like pentosidine, would provide invaluable insight into whether supplementation can improve the material quality of the bone matrix itself.

Other important unanswered questions include the determination of optimal **dose-response relationships** and the **long-term sustainability of benefits** after supplementation is discontinued.¹³ Most studies use fixed doses, and it is unclear if higher doses yield greater benefits or if a lower maintenance dose is sufficient after an initial loading period.

6.3 Recommendations for Clinical Application and Future Investigation

Based on the current weight of evidence, long-term oral supplementation with a high-quality, hydrolyzed Type I collagen peptide product, typically at a dose of 5 to 10 grams per day, represents a promising and generally safe complementary strategy for supporting bone and skin health in aging populations, particularly postmenopausal women. For bone health, it should be considered an adjunct to, not a replacement for, standard osteoporosis management, which includes adequate calcium and vitamin D intake, weight-bearing exercise, and pharmacological agents where indicated. For skin health, it serves as a foundational "inside-out" approach to complement topical treatments and photoprotection.

To advance the field and provide more definitive clinical guidance, future research should prioritize the following:

1. **Design and execute a large-scale, long-term, placebo-controlled RCT with a dual-endpoint design** to directly and simultaneously assess the effects of collagen supplementation on validated bone parameters (BMD, TBS, P1NP, CTX) and skin parameters (wrinkle profilometry, elasticity, dermal density) in an aging population.
2. **Incorporate advanced analytical methods into human trials**, including HR-pQCT to

measure bone microarchitecture and mass spectrometry-based analysis of serum/urine to quantify biomarkers of collagen cross-linking (e.g., pentosidine).

3. **Conduct head-to-head comparative trials** of different commercially available collagen hydrolysates to determine if specific sources, hydrolysis methods, or peptide profiles yield superior clinical outcomes.
4. **Expand the scope of research to include underrepresented populations**, most notably aging men, to determine if the benefits observed in postmenopausal women are generalizable.

By addressing these critical gaps, the scientific community can fully elucidate the systemic impact of collagen supplementation and solidify its role as an evidence-based intervention for promoting healthy aging of the skeletal and integumentary systems.

Works cited

1. Collagen benefits: Should I take a supplement? | MD Anderson Cancer Center, accessed on October 3, 2025, <https://www.mdanderson.org/cancerwise/should-i-take-a-collagen-supplement.h00-159462423.html>
2. Collagen and the Battle Against Skin Aging - McGill University, accessed on October 3, 2025, <https://www.mcgill.ca/oss/article/student-contributors-general-science/collagen-and-battle-against-skin-aging>
3. Type I And Type III Collagen - Consensus Academic Search Engine, accessed on October 3, 2025, <https://consensus.app/questions/type-i-and-type-iii-collagen/>
4. Regulation of Collagen I and Collagen III in Tissue Injury and Regeneration, accessed on October 3, 2025, <http://www.fortunejournals.com/articles/regulation-of-collagen-i-and-collagen-iii-in-tissue-injury-and-regeneration.html>
5. The ultimate guide to collagen types I, II and III - Holland & Barrett, accessed on October 3, 2025, <https://www.hollandandbarrett.com/the-health-hub/vitamins-and-supplements/supplements/collagen/the-ultimate-guide-to-collagen-types-i-ii-and-iii/>
6. Changes in bone collagen with age and disease, accessed on October 3, 2025, <https://www.ismni.org/jmni/pdf/10/11Bailey.pdf>
7. Bone biology - International Osteoporosis Foundation, accessed on October 3, 2025, <https://www.osteoporosis.foundation/health-professionals/about-osteoporosis/bone-biology>
8. The Effects of Type I Collagen Hydrolysate Supplementation on Bones, Muscles, and Joints: A Systematic Review - PubMed Central, accessed on October 3, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11842160/>
9. Specific collagen peptides in osteoporosis management: Unraveling therapeutic potential through expert perspectives and scientific, accessed on October 3, 2025, <https://www.orthopaper.com/archives/2024/vol10issue1/PartC/10-1-9-644.pdf>

10. Science - Phoscollagen, accessed on October 3, 2025,
<https://www.phoscollagen.com/science/>
11. Efficacy of collagen peptide supplementation on bone and muscle health: a meta-analysis, accessed on October 3, 2025,
<https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1646090/full>
12. Type III collagen regulates osteoblastogenesis and the quantity of trabecular bone - PMC, accessed on October 3, 2025,
<https://PMC.ncbi.nlm.nih.gov/articles/PMC4335719/>
13. Oral Collagen Supplementation: A Systematic Review of ..., accessed on October 3, 2025,
<https://jddonline.com/articles/oral-collagen-supplementation-a-systematic-review-of-dermatological-applications-S1545961619P0009X/>
14. A Review of the Effects of Collagen Treatment in Clinical Studies - MDPI, accessed on October 3, 2025, <https://www.mdpi.com/2073-4360/13/22/3868>
15. Regulation of Collagen I and Collagen III in Tissue Injury and ..., accessed on October 3, 2025, <https://PMC.ncbi.nlm.nih.gov/articles/PMC9912297/>
16. Collagen Production And Aging - Consensus Academic Search Engine, accessed on October 3, 2025,
<https://consensus.app/questions/collagen-production-and-aging/>
17. Skin Aging and Type I Collagen: A Systematic Review of Interventions with Potential Collagen-Related Effects - MDPI, accessed on October 3, 2025,
<https://www.mdpi.com/2079-9284/12/4/129>
18. Collagen - The Nutrition Source - Harvard University, accessed on October 3, 2025, <https://nutritionsource.hspf.harvard.edu/collagen/>
19. Study indicates collagen peptides can increase bone density - UCLA Health, accessed on October 3, 2025,
<https://www.uclahealth.org/news/article/study-indicates-collagen-peptides-can-increase-bone-density>
20. Dermatologist Weighs In On Collagen Peptide Treatments - Hackensack Meridian Health, accessed on October 3, 2025,
<https://www.hackensackmeridianhealth.org/en/healthu/2022/07/26/dermatologist-weighs-in-on-collagen-peptide-treatments>
21. Collagen in Women's Health: Beyond Healthy Skin, accessed on October 3, 2025, <https://plminstitute.org/plmi-blog/collagen-in-womens-health-beyond-healthy-skin/>
22. Decreased Collagen Production in Chronologically Aged Skin ..., accessed on October 3, 2025, <https://PMC.ncbi.nlm.nih.gov/articles/PMC1606623/>
23. Age-related changes in the proportion of types I and III collagen - PubMed, accessed on October 3, 2025, <https://pubmed.ncbi.nlm.nih.gov/3266279/>
24. (PDF) Collagen cross-links as a determinant of bone quality: A ..., accessed on October 3, 2025,
https://www.researchgate.net/publication/26817704_Collagen_cross-links_as_a_determinant_of_bone_quality_A_possible_explanation_for_bone_fragility_in_aging_osteoporosis_and_diabetes_mellitus

25. (PDF) Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women—A Randomized Controlled Study - ResearchGate, accessed on October 3, 2025, https://www.researchgate.net/publication/322545231_Specific_Collagen_Peptides_Improve_Bone_Mineral_Density_and_Bone_Markers_in_Postmenopausal_Women-A_Randomized_Controlled_Study
26. Specific Collagen Peptides Improve Bone Mineral Density and Bone ..., accessed on October 3, 2025, <https://pubmed.ncbi.nlm.nih.gov/29337906/>
27. Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women—A Randomized Controlled Study - MDPI, accessed on October 3, 2025, <https://www.mdpi.com/2072-6643/10/1/97>
28. Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women—A Randomized Controlled Study - PMC, accessed on October 3, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5793325/>
29. Collagen Science Update – March 2025 Edition, accessed on October 3, 2025, <https://collagenalliance.org/collagen-science-update-march-2025-edition/>
30. Specific Bioactive Collagen Peptides in Osteopenia and Osteoporosis: Long-Term Observation in Postmenopausal Women - Journal of Bone Metabolism, accessed on October 3, 2025, <https://www.e-jbm.org/m/journal/view.php?doi=10.11005/jbm.2021.28.3.207>
31. Specific Bioactive Collagen Peptides in Osteopenia and Osteoporosis: Long-Term Observation in Postmenopausal Women - PMC, accessed on October 3, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8441532/>
32. Bone Turnover Markers: Basic Biology to Clinical Applications - Oxford Academic, accessed on October 3, 2025, <https://academic.oup.com/edrv/article/44/3/417/6889555>
33. Bone turnover markers are biochemical markers of either bone formation or bone resorption. Commercially available tests are avai - Blue Cross Blue Shield of Rhode Island, accessed on October 3, 2025, <https://www.bcbsri.com/providers/sites/providers/files/policies/2025/02/2025%20Bone%20Turnover%20Markers%20for%20Diagnosis%20and%20Management%20of%20Osteoporosis%20and%20Diseases%20Associated%20with%20High%20Bone%20Turnover.pdf>
34. Large-factor Micro-CT super-resolution of bone microstructure - Frontiers, accessed on October 3, 2025, <https://www.frontiersin.org/journals/physics/articles/10.3389/fphy.2022.997582/full>
35. Bone Cortical And Cancellous - Physiopedia, accessed on October 3, 2025, https://www.physio-pedia.com/Bone_Cortical_And_Cancellous
36. Biomechanics and Mechanobiology of Trabecular Bone: A Review - PMC - PubMed Central, accessed on October 3, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC5101038/>
37. Interest of Bone Histomorphometry in Bone Pathophysiology Investigation: Foundation, Present, and Future - Frontiers, accessed on October 3, 2025, <https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.907914/full>

38. MicroCT Lab | BCM - Baylor College of Medicine, accessed on October 3, 2025, <https://www.bcm.edu/research/research-service-labs/microct-lab>
39. Rat Model for Osteoporosis - Enamine, accessed on October 3, 2025, <https://enamine.net/biology/animal-studies/pathology-models-for-efficacy-studies/rat-model-osteoporosis>
40. Ovariectomy Induced Osteoporosis Animal Models - Biocytogen, accessed on October 3, 2025, <https://biocytogen.com/product/ovariectomy-induced-osteoporosis-model>
41. Effect of Collagen Peptide, Alone and in Combination with Calcium Citrate, on Bone Loss in Tail-Suspended Rats, accessed on October 3, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC7070256/>
42. Effect of Collagen Peptide, Alone and in Combination with Calcium Citrate, on Bone Loss in Tail-Suspended Rats - MDPI, accessed on October 3, 2025, <https://www.mdpi.com/1420-3049/25/4/782>
43. Collagen peptides promote osteogenesis and angiogenesis by ..., accessed on October 3, 2025, <https://mednexus.org/doi/full/10.1097/CM9.0000000000003458>
44. In Vitro and In Vivo Bone-Forming Effect of a Low-Molecular-Weight ..., accessed on October 3, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10940753/>
45. Jumping Exercise Combined With Collagen Supplementation Preserves Bone Mineral Density in Elite Cyclists in - Human Kinetics Journals, accessed on October 3, 2025, <https://journals.humankinetics.com/view/journals/ijsnem/34/1/article-p38.xml>
46. Jumping Exercise Combined With Collagen Supplementation Preserves Bone Mineral Density in Elite Cyclists - PubMed, accessed on October 3, 2025, <https://pubmed.ncbi.nlm.nih.gov/37883634/>
47. Does Collagen Powder Actually Improve Skin Health? - Dallas Associated Dermatologists, accessed on October 3, 2025, <https://dallasassocderm.com/does-collagen-powder-actually-improve-skin-health/>
48. Collagen Supplements for Aging and Wrinkles: A Paradigm Shift in the Fields of Dermatology and Cosmetics - PMC, accessed on October 3, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8824545/>
49. A Clinical Trial Shows Improvement in Skin Collagen, Hydration ..., accessed on October 3, 2025, <https://pubmed.ncbi.nlm.nih.gov/39021368/>
50. The Effects of Oral Collagen Supplementation on Skin Aging | Quality in Sport, accessed on October 3, 2025, <https://apcz.umk.pl/QS/article/view/53977>
51. Oral intake of collagen peptide NS improves hydration, elasticity, desquamation, and wrinkling in human skin: a randomized, double-blinded, placebo-controlled study - RSC Publishing - The Royal Society of Chemistry, accessed on October 3, 2025, <https://pubs.rsc.org/en/content/articlehtml/2023/fo/d2fo02958h>
52. Anti-Aging Effects of Low-Molecular-Weight Collagen Peptide Supplementation on Facial Wrinkles and Skin Hydration: Outcomes from a Six-Week Randomized, Double-Blind, Placebo-Controlled Trial - MDPI, accessed on October 3, 2025, <https://www.mdpi.com/2079-9284/11/4/137>

53. Effects of Oral Collagen for Skin Anti-Aging: A Systematic Review and Meta-Analysis - PMC, accessed on October 3, 2025,
<https://PMC.ncbi.nlm.nih.gov/articles/PMC10180699/>
54. Effects of Oral Collagen for Skin Anti-Aging: A Systematic Review and Meta-Analysis - MDPI, accessed on October 3, 2025,
<https://www.mdpi.com/2072-6643/15/9/2080>
55. (PDF) Effects of Oral Collagen Supplementation on Skin Aging - ResearchGate, accessed on October 3, 2025,
https://www.researchgate.net/publication/383314184_Effects_of_Oral_Collagen_Supplementation_on_Skin_Aging
56. Collagen supplementation for skin health: A mechanistic systematic review - PubMed, accessed on October 3, 2025,
<https://pubmed.ncbi.nlm.nih.gov/32436266/>
57. Collagen supplementation in skin and orthopedic diseases: A review of the literature - PMC, accessed on October 3, 2025,
<https://PMC.ncbi.nlm.nih.gov/articles/PMC10102402/>
58. The effects of collagen peptide supplementation on body composition, collagen synthesis, and recovery from joint injury and exercise: a systematic review - PMC, accessed on October 3, 2025, <https://PMC.ncbi.nlm.nih.gov/articles/PMC8521576/>
59. Collagen Supplementation for Joint Health: The Link between Composition and Scientific Knowledge - PMC - PubMed Central, accessed on October 3, 2025,
<https://PMC.ncbi.nlm.nih.gov/articles/PMC10058045/>
60. Study Details | NCT06240429 | Collagen Peptide Supplementation and Physical Exercise in Older Adults | ClinicalTrials.gov, accessed on October 3, 2025,
<https://www.clinicaltrials.gov/study/NCT06240429>
61. Collagen and Peptides: Mechanisms, Health Effects, and The Population Biological Mechanisms of Collagen and Peptides - ResearchGate, accessed on October 3, 2025,
https://www.researchgate.net/publication/395457255_Collagen_and_Peptides_Mechanisms_Health_Effects_and_The_Population_Biological_Mechanisms_of_Collagen_and_Peptides
62. Biological Effect of Hydrolyzed Collagen on Bone Metabolism | Request PDF - ResearchGate, accessed on October 3, 2025,
https://www.researchgate.net/publication/276295853_Biological_Effect_of_Hydrolyzed_Collagen_on_Bone_Metabolism
63. Osteogenic Activity of Collagen Peptide via ERK/MAPK Pathway ..., accessed on October 3, 2025, <https://www.mdpi.com/1420-3049/18/12/15474>
64. Bovine Collagen Peptides Compounds Promote the Proliferation and Differentiation of MC3T3-E1 Pre-Osteoblasts | PLOS One - Research journals, accessed on October 3, 2025,
<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0099920>
65. A Food Supplement of Hydrolyzed Collagen Improves ..., accessed on October 3, 2025,
https://www.researchgate.net/publication/46576853_A_Food_Supplement_of_Hydrolyzed_Collagen_Improves_Compositional_and_Biodynamic_Characteristics_of

Vertebrae in Ovariectomized Rats

66. bonebalance comprises collagen peptides to build a healthy bone matrix, accessed on October 3, 2025,
<https://bonebalance.co.uk/how-bonebalance-works/>
67. Effect of collagen peptides intake on skin conditions: a clinical trial - AgroFOOD Industry Hi Tech 35(2) 2024, accessed on October 3, 2025,
https://digital.teknoscienze.com/agrofood_industry_hi_tech_35_2_2024/collagen_-effect_of_collagen_peptides_intake_on_skin_conditions_a_clinical_trial
68. Collagen supplementation in skin and orthopedic diseases: A review of the literature, accessed on October 3, 2025,
https://www.researchgate.net/publication/369597754_Collagen_supplementation_in_skin_and_orthopedic_diseases_A_review_of_the_literature
69. A Review of the Effects of Collagen Treatment in Clinical Studies - PMC, accessed on October 3, 2025, <https://pmc.ncbi.nlm.nih.gov/articles/PMC8620403/>
70. Collagen peptides may improve bone health in osteopenia - Study Summary - Examine.com, accessed on October 3, 2025,
<https://examine.com/research-feed/study/OdnLj0/>
71. The Effects of Type I Collagen Hydrolysate Supplementation on Bones, Muscles, and Joints: A Systematic Review, accessed on October 3, 2025,
<https://orthopedicreviews.openmedicalpublishing.org/article/129086-the-effects-of-type-i-collagen-hydrolysate-supplementation-on-bones-muscles-and-joints-a-systematic-review>